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Topotecan (TpT) is amajor inhibitory compound of topoisomerase (topo) I that plays important roles in gene transcription and cell
division. We have previously reported that heparin and heparan sulfate (HS) might be transported to the cell nucleus and they can
interact with topoisomerase I. We hypothesized that heparin and HS might interfere with the action of TpT. To test this hypothesis
we isolated topoisomerase I containing cell nuclear protein fractions from normal liver, liver cancer tissues, and hepatoma cell lines.
The enzymatic activity of these extracts was measured in the presence of heparin, liver HS, and liver cancer HS. In addition, topo
I activity, cell viability, and apoptosis of HepG2 and Hep3B cells were investigated after heparin and TpT treatments. Liver cancer
HS inhibited topo I activity in vitro. Heparin treatment abrogated topo I enzyme activity in Hep3B cells, but not in HepG2 cells,
where the basal activity was higher. Heparin protected the two hepatoma cell lines from TpT actions and decreased the rate of TpT
induced S phase block and cell death. These results suggest that heparin and HS might interfere with the function of TpT in liver
and liver cancer.
1. Introduction
Heparin and heparan sulfate (HS) are polysulfated sugars,
members of glycosaminoglycans (GAGs), present in animal
and human tissue in free or protein bound forms.
Heparan sulfate glycanated proteins are found in the
extracellular matrix and on the cell surface [1]. Recent studies
provide ample evidence on the central role of thesemolecules
in cell life including cellular organization, cell behavior, and
cell signaling [1, 2].Heparin undheparan sulfates bind several
growth factors [3–7], hormones [8], cytokines [6, 9], and
chemokines [10, 11] that are implicated in cell regulation [12]
in several ways.
The cellular role of HS has been studied for years
without a major breakthrough achieved [13–18]. Biochemical
approaches failed to collect convincing data for intracellu-
lar proteoglycan activity. Recently tentative evidences were
provided supporting the regulatory effect of HS on cell
proliferation and showing that these GAGs affect DNA-
transcription factor interactions [19]. Our previous experi-
ments resulted in similar conclusions [17]. For the first time
confocal microscopy evidenced the nuclear localization of
GAGs and proteoglycans [20–22]. Since then the nuclear
function of proteoglycans is coming to focus of interest [22].
Nevertheless, the issue is still an elusive part of proteoglycan
research.
We reported that heparin and liverHS inhibit the plasmid
relaxation activity of topoisomerase I enzyme in vitro [21].
Furthermore, we provided evidence for heparin and HS cel-
lular uptake and accumulation in the nucleus [17, 22]. These
observations motivated us to investigate if GAG molecules
are able to interfere with topoisomerase I (topo I) activity and
modify the effect of topo I inhibitory drug topotecan (TpT)
[23].
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2. Materials
2.1. Liver Tissue. Surgical specimens from cancer patients
were sent to our department for histological diagnosis and
were used with the permission of the regional ethical com-
mittee.The samples were frozen in liquid nitrogen and stored
at −80∘C until used.
2.2. Cells. American Tissue Type Culture Collection HepG2
andHep3B cell lineswere used after 12–15 passages. Cellswere
plated at a density of 2 × 105 cells/mL into six-well plates in
2mL/well Dulbecco’s modified Eagle’s mediumwith 5% (v/v)
fetal calf serum (GIBCO-BRL).
2.3. Chemicals. Unless specified otherwise, the chemicals
were purchased from Merck (Darmstadt, Germany). Hind
III and Klenow DNA polymerase enzymes were obtained
from Promega (Madison, USA). Topotecan was a gift of
SmithKline Beecham (King of Prussia, USA). Heparin was
purchased from Sigma (Steinheim, Germany).
Protein concentration was determined by using the
Coomassie protein assay kit of Pierce (Rockford, USA).
Recombinant topo I and polyclonal human anti-topo I IgG
(scl-70) from Topogen (Columbus, USA) were used for
western blot.
3. Methods
3.1. Cell Numbers, Viability, and Morphology. Mitochondrial
succinate dehydrogenase activity [24] was determined by 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) test, and cell numbers were counted in a hemocy-
tometer.
Morphology of the two hepatoma cell lines was studied
either by growing them onto coverslips or by preparing
cytospin slides. Cells were visualized with hematoxyline-
eosine staining.
3.2. Determination of Cell Cycle Parameters. HepG2 and
Hep3B cells were washed twice with PBS then suspended in
a buffer containing 0.1% sodium citrate, 0.1% Triton X-100,
and 0.05mg/mL ribonuclease, pH 7.7, at 106 cell/mL density.
Before the analysis, the cells were stained with 50 𝜇g/mL
propidium-iodide (Sigma, Steinheim, Germany).
Cell cycle parameters were measured on a FACScan
flow cytometer (Becton Dickinson, San Jose, USA) scanning
the propidium-iodide signals and the forward and side
scatter parameters. The Multicycle software of Robinovitch
(Phoenics Flow San Diego, USA) was used for analyzing the
results.
3.3. Protein and GAG Isolation, Quantification. Nuclei from
liver specimens were isolated on saccharose gradient, accord-
ing to Hogeboom [25]. The method of Duguet was used
when nuclei were isolated from hepatoma cell lines [26].
Isolation was carried out in the presence of 1.0mM
phenyl-methylsulfonyl fluoride (PMSF). Nuclei were further
extracted with 0.35M NaCl buffer as described elsewhere
[27]. Protein concentration of the nuclear extract was deter-
mined by the Coomassie protein kit of Pierce Biotechnology,
Inc. (Rockford, USA) according to the protocol of the manu-
facturer. The isolation of GAG and HS, their electrophoresis,
and their colorimetry were described previously [17, 21, 28].
3.4. Topoisomerase I Relaxation Assay. ATP independent
relaxation of supercoiled pBR322 plasmid Stratagene (La
Jolla, USA) was done in standard 30 𝜇L reaction mixture
containing various amounts of 0.35M NaCI nuclear protein
extract, 0.5 𝜇g supercoiled plasmid DNA, 40mM Tris-HCl,
pH 7.5, 100mM KCl, 10mM MgCI, 2.5mM dithiotreitol,
0.5mM EDTA, 1mM phenyl-methylsulfonyl fluoride, and
1 𝜇g bovine serum albumin (as carrier protein) [29]. Samples
were incubated at 37∘C for 30min with or without various
GAGs as indicated. The addition of GAGs did not influence
the pH of the reaction mixture. Enzymatic reactions were
terminated by adding 1 𝜇L 10% sodium dodecylsulfate and
1 𝜇L (10mg/mL) proteinase K. Relaxation of supercoiled
DNA plasmid was determined by running the samples on
analytical 1% agarose gel in Tris-boric acid buffer (50mM
Tris, 5mM boric acid, 1mM EDTA, pH 8.1.) for 12 h at 24V.
Gels were poststained with 0.1 𝜇g/mL ethidium bromide and
visualized under UV light [29].
3.4.1. Plasmid Cleavage Reaction for Topoisomerase I. pBR322
plasmid was linearized with EcoRI enzyme and then end-
labeled with 5 𝜇Ci 𝛼32 dATP and 20U Klenow DNA poly-
merase at 30∘C for 15min. Heating at 75∘C for 10min
terminated the reaction. The labeling was removed from one
end of the plasmid by Hind III digestion. Unincorporated
radioactivity was separated by filtration through a Sephadex
G50 (Pharmacia, Uppsala, Sweden) column. Ten microgram
protein from the 0.35M NaCI extract of liver or cancer cell
nuclei was coincubatedwith 100 𝜇Mtopotecan and 8000 cpm
labeled plasmid with or without 2𝜇M heparin for 10min.
The reaction was terminated with SDS and proteinase as
described above and the samples were run on 1% agarose gel
with denaturing sample buffer (0.45MNaOH).The gels were
dried and exposed to Kodak X-omat film [29].
3.4.2. Electrophoretic Mobility Shift Assay to Study the Compe-
tition of DNA and Heparin for Topoisomerase I. pBluescript
plasmid was digested with Hpa II restriction enzyme. One
of the restriction fragments with 516 base pair was separated
and labeled withDIG-11 dUTP and terminal deoxynucleotide
transferase (Roche, Mannheim, Germany), as suggested by
the manufacturer. Based on its sequence analysis the labeled
fragment contained 8 potential topoisomerase I binding
sequences [30]. Ten unit purified topoisomerase I enzyme
was incubated with 35 ng digoxigenin labeled DNA fragment
in 40mM Tris-HCl pH 7.5, 100mM KCl, 10mM MgCl,
2.5mM dithiotreitol, and 0.5mM EDTA. 1mM phenyl-
methylsulfonyl fluoride and 1 𝜇g bovine serum albumin (as
carrier protein) in a total volume of 20 𝜇L. Identical reaction
mixtures were supplemented with 10 or 100 ng commercial
heparin. Incubationwas carried out at 37∘C for 15min. Subse-
quently, the samples were run on 1.2% agarose gel and blotted
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Table 1: (a) Effect of heparin and TpT on cell cycle parameters of HepG2 and Hep3B cells (results of 3 independent experiments).
Concentrations used: TpT 1 𝜇M, heparin 100𝜇g/mL. TpT treatment resulted in significant alterations (𝑃 < 0.05) of cell cycle parameters
in both cell lines. Heparin did not change the cell cycle parameters (𝑃 > 0.05). S phase protection of heparin at combined treatment was
statistically significant only in case of Hep3B cells. (b) Induction of apoptosis after TpT and heparin treatment. Proportion of dead/apoptotic
cells after TpT and heparin treatment. Concentrations: TpT 1𝜇M, heparin 100𝜇g/mL. Values corresponding to the apoptosis gate of cell cycle
represent the average of three experiments. TpT induced significant increase in apoptosis compared to the control in both cell lines. Heparin
raised the proportion of apoptotic cells as compared to the controls for HepG2, but not for Hep3B cells. Significant decrease of dead cell
fraction was found after a combined heparin and TpT treatment at both cell lines.
(a)
% of cells HepG2 Hep3B
Treatment G1 S G2 G1 S G2
Control 52,6 ± 4,08 35,7 ± 3,29 11,6 ± 2,19 78,7 ± 0,42 15,9 ± 0,14 5,5 ± 0,28
1 𝜇MTpT 15,8 ± 1,31 80,8 ± 15,51 4,2 ± 0,071 2,06 ± 0,071 65,6 ± 0,991 13,7 ± 1,061
100 𝜇g/mL Heparin 58,9 ± 1,39 28,3 ± 3,58 12,8 ± 0,59 81,1 ± 0,28 14 ± 0,28 5 ± 0,07
Hp + TpT 14,5 ± 0,45 70,2 ± 3,973 15,2 ± 0,68 35,4 ± 0,1 56,4 ± 2,332 8,1 ± 2,4
1Student’s 𝑡-test: 𝑃 < 0.02 for HepG2, 𝑃 < 0.005 for Hep3B (TpT compared to control).
2Student’s 𝑡-test: 𝑃 < 0.005 (Hp + TpT compared to TpT alone).
3Student’s 𝑡-test: 𝑃 > 0.1 (Hp + TpT compared to TpT alone).
(b)
%-of cells in apoptotic gate HepG2 Hep3B
Control 5,65 ± 0,595 3,53 ± 0,93
1 𝜇MTpT 18,67 ± 3,531 16,49 ± 0,8211
100𝜇g/mL heparin 9,06 ± 0,162 2,48 ± 0,22
Hp + TpT 12,69 ± 2,343 4,44 ± 1,073
1Student’s 𝑡-test: 𝑃 < 0,001 (TpT compared to control).
2Student’s 𝑡-test: 𝑃 < 0,05 (Hp compared to control).
3Student’s 𝑡-test: 𝑃 < 0,05 (Hp + TpT compared to TpT alone).
to positively charged nylon membrane (Boehringer (Roche),
Mannheim, Germany). The positions of the DNA bands
were visualized by sheep alkaline phosphatase-conjugated
antidigoxigenin Fab fragments (Roche, Mannheim, Ger-
many), using NBT and BCIP (Roche Applied Science) as
chromogens.
3.4.3. Analysis of the Raw Data. The assays have been run
in triplicates and statistical significance has been calculated
based on data distribution (normal or non-parametric) using
a Student’s t-test or a Mann-Whitney test using Graphpad
Prism 4.03 (Graphpad Software Inc., Suite, La Jolla, CA,
USA).
4. Results
4.1. Influence of Heparin on Topotecan-Induced Cell Growth
Retardation. To assess the interference of heparin with TpT,
the two hepatoma cell lines were treated with 1 𝜇M TpT
alone or together with 100 𝜇g/mL heparin. The effect was
evaluated measuring the growth parameters of untreated or
heparin treated cells. After 48 h of plating, the serum has
been withdrawn and the action of heparin and topotecan
was studied under serum-free conditions. Cells were counted
daily. Figures 1(a) and 1(b) show that both cell lines reached
the exponential phase of cell growth around 48 h after plating.
Inhibitory action of TpT occurred at 72 h and was exerted
continuously thereafter (𝑃 < 0.001 with Student’s t-test).
The growth of both hepatoma cell lines was inhibited by
100 𝜇g/mL heparin, but at a lower extent than by TpT
(𝑃 > 0.05 with Student’s t-test for HepG2, 𝑃 = 0.02
for Hep3B). A combined treatment revealed that heparin is
capable of rescuing the cells against TpT action. This effect
was statistically significant in Hep3B cells (𝑃 < 0.001 with
Student’s t-test), but not in HepG2 cells (𝑃 > 0.1).
4.2. Changes in Cell Cycle Parameters. Although heparin
inhibited the proliferation of both hepatoma lines, no changes
in cell cycle parameters were discernable. TpT induced dra-
matic G1-S phase block and cell death in both cell lines. Both
effects were reduced when TpT was administered together
with heparin (Table 1(a)). After TpT exposure, the ratio of
apoptotic cells increased more than three and four times in
HepG2 andHep3B cells, respectively.This level fell back to the
original value after the combined heparin + TpT treatment of
Hep3B cell line, while only 30% protection was achieved in
case of HepG2 cells (Table 1(b)). The S phase block decreased
with 13% compared to TpT treatment in both cell lines, which
was statistically significant only in Hep3B cells (Table 1(a)).
4.3. Topoisomerase I Activity of Liver Specimens. The topo I
enzymatic activities of surgically removed human liver and
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Figure 1: Effects of heparin andTpTonHepG2 (panel a) andHep3B (panel b) cell numbers after 48–120 h incubation (results of 3 independent
experiments). After 48 h of plating, serum has been withdrawn and the action of heparin and TpT was studied under serum-free conditions.
Cells were grown for 72 h in the presence of 1 𝜇M TpT, 100 𝜇g/mL heparin alone, or in combination of the two. The curves represent the
average of 6 parallels. Cells were counted daily. Both cell lines reached the exponential phase of cell growth around 48 h. Inhibitory action of
TpT occurred at 72 h, which was exerted continuously thereafter (difference is significant with Student’s t-test 𝑃 < 0.001). 100𝜇g/mL heparin
inhibited the growth of both hepatoma cell lines, but at a lower extent than TpT (𝑃 > 0.05 with Student’s t-test for HepG2, 𝑃 = 0.02 for
Hep3B). In combined treatment heparin rescued the cells against TpT action. The protection was significant for Hep3B cells (b) (𝑃 < 0.001
with Student’s t-test), but not for HepG2 cells (Figure 1 (a)) (𝑃 > 0.1).
R
S
A 1 2 3 4
(a)
R
S
A 1 2 3 4
(b)
1 2 3 Mw 4 5 6 7
116
76
53
(kDa)
(c)
Figure 2: Differences of topoisomerase I activity in liver samples (a) and in hepatoma cells (b) (representative image of three independent
experiments). Topoisomerase I activities in liver samples (a) and hepatoma cell lines (b) of 250 and 500 ng nuclear extract from peritumoral
liver (a 1, a 2), hepatocellular carcinoma (a 3, a 4), HepG2 (b 1, b 2), and Hep3B cells (b 3, b 4). The activities of the specimens are related to
the amounts of topoisomerase I protein in the cell nuclear extracts, as it is demonstrated on a western blot (c). Lane 1: Hep3B, lanes 2 and 3:
HepG2, lanes 4 and 6: hepatocellular carcinomas, and lanes 5 and 7: peritumoral liver tissues. In addition to the 120 kDa band of the whole
protein, the antibody reacts with more degradation products of the enzyme, including the 67 kDa catalytic fragment. A: plasmid control
without cell nuclear extract. R: relaxed, S: supercoiled plasmid.
hepatocellular carcinomas as well as those of two hepatoma
cell lines were studied. Nuclear extracts from peritumoral
liver specimens showed low topo I activity. In contrast,
200 ng of nuclear protein from liver cancer resulted in total
relaxation of the pBR322 plasmid. An identical amount
of protein from peritumoral liver left more than half of
the plasmid unattached. The activity in HepG2 cells was
as high as in the primary liver cancer. Interestingly the
less differentiated Hep3B hepatoma cell line retained only
moderated topoisomerase I activity (Figures 2(a) and 2(b)).
Western blots loaded with 15𝜇g of nuclear protein
extracts indicated that the measured activities were linearly
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Figure 3: Differences of topoisomerase I plasmid cleavage activity
trapped by TpT in liver samples and in hepatoma cells (represen-
tative image of three independent experiments). pBR322 plasmid
was linearized and end-labeled with 5 𝜇Ci 𝛼32P ATP by using
20U Klenow DNA polymerase. To remove the labeling from one
end, the linearized plasmid was digested with Hind III restriction
endonuclease. Ten microgram 0.35M NaCI nuclear extracts of
HepG2, Hep3B, and human HCC specimens were incubated with
8000 cpm linearized plasmid in the absence or presence of 100 and
200 𝜇M topotecan. Lanes 1: cleavage reaction without topotecan,
lane 2: cleavage reaction with 100𝜇Mtopotecan, and lane 3: cleavage
reaction with 200 𝜇M topotecan. The activity of Hep3B extract was
much lower than that of HepG2 and human Iiver cancer.
dependent on the amounts of topoisomerase protein in the
cells. A significantly higher amount of topo I protein was
detected in HepG2 cells and primaryHCC than in the Hep3B
cell line. The protein in peritumoral livers was below the
detection level (Figure 2(c)). The cleavage reaction of TpT-
trapped enzyme corroborated the activity of the liver and
tumor samples. When using 10 𝜇g HepG2 and human HCC
nuclear extract, a complete fragmentation of the end-labeled
plasmid was observed in the presence of 100 𝜇M TpT. The
same amount of Hep3B nuclear protein was considerably less
effective (Figure 3).
4.4. Inhibitory Action of Glycosaminoglycans on Topoiso-
merase I Activities. Nuclear extracts with high topoisomerase
I activity from HepG2 cells and a surgically removed
hepatoma were used to assess the inhibitory potential of
commercial heparin, normal liver HS, human hepatocellular
carcinoma, and peritumoral liver tissue GAG specimens on
topo I plasmid relaxation and TpT-trapped cleavage reaction.
All GAG specimens but HS from liver carcinoma inhibited
the plasmid relaxation assay in a dose-dependent manner.
In this measure, commercial heparin was the most effective
confirming an earlier report [23].
In cleavage reactions, the efficacy of heparin and normal
liver HS was identical. Peritumoral liver GAG inhibited the
cleavage better than the HCC GAG did (not shown). When
this experiment was repeated by using isolated peritumoral
and HCC HS, the result was similar (Figure 4) indicating
that heparan sulfate is the active GAG component and is
responsible for the inhibitory activity. The inhibitory action
of GAGs depended on the topoisomerase I activity of the
nuclear extract. Even liver cancer HS decreased the TpT-
induced cleavage reaction of Hep3B cells (Figure 4).
We also studied if this phenomenon, observed in a cell-
free system, can also be detected when cell cultures were
treated with heparin. To this end, hepatoma cell lines were
treated with 100𝜇g/mL heparin for 24 and 48 h. Thereafter,
nuclear extracts were prepared and used for plasmid relax-
ation, as it is shown in Figure 5. Cell nuclear extracts of
heparin-treated Hep3B cells did not exert topo I activity.
Nevertheless, an identical amount of heparin could not
inhibit the activity of the enzyme in HepG2 cells.
4.5. Competition of Heparin and DNA for Topoisomerase I.
As topoisomerase I is a heparin-binding protein, we tested if
heparin competed with the DNA for the enzyme. Changes in
the electrophoretic mobility shift indicated that 10𝜇g heparin
effectively inhibited the mobility shift caused by 10 unit topo
I enzyme on 35 ng DNA (Figure 6).
5. Discussion
Our previous studies on various human cancer specimens
revealed that the increase in the amount of proteoglycans and
their sugar components is one of the most striking features
of these tumors [31, 32]. As a general rule, we found about
tenfold increase of chondroitin sulfate and fivefold increase of
heparan sulfate in surgically removed liver and kidney cancer
tissues. The biological significance of these changes awaited
explanation. The pharmacological effects of heparin have
been known for a long time, but contradictory observations
were reported on its capacity to inhibit cell proliferation [33–
36]. While heparin is mainly present in mast cells, HS that is
structurally strongly related to heparin is present everywhere
in the living organisms [37]. Earlier we demonstrated that
cells could take up labeled heparin and liver HS and transport
them into the nucleus [17, 21].
Furthermore, not only GAGs but also proteoglycans have
been detected in the nucleus [38]. One possible role of
nuclear HS is to shuttle the nuclear transport of heparin-
binding growth factors, such as basic fibroblast growth factor
(FGF-2). Once in the nucleus, these growth factors might
directly modulate cellular activities [39]. A less-known way
of regulation of this process is through heparanase enzyme,
an endoglycosidase, implicated in cancer progression and
metastasis [40, 41]. Heparanase can be localized to both the
plasma membrane and the nucleus, and thus its interference
with action of heparin is conceivable. Both its localization and
cellular levels are finely regulated [42].
The evidences for the regulatory significance of heparin
and HS justify our efforts to look for physiological or
pathological cell nuclear functions where heparan sulfates
could be involved [43]. We addressed the question if heparin
induced inhibition of cell proliferation might be related to its
ability to bind and inactivate nuclear proteins. We focused
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Figure 4: Inhibitory effect of heparin, normal and peritumoral liver heparane sulfate (HS), and hepatocellular carcinoma heparane sulfate
on the TpT induced topo I cleavage reaction (representative image of three independent experiments). The origin of nuclear extracts: (a):
hepatocellular carcinoma; (b): HepG2 cells; (c): Hep3B cells. The reaction mixture contained pBR322 plasmid DNA, nuclear extracts as
described, 100 𝜇M topotecan in all samples as well as in the positive controls. In negative control topotecan was not added. Types and
concentrations of GAGs are as follows: (a1): heparin 1𝜇M; (a, b, c 2): heparin 2 𝜇M; (a3): normal liver HS 1 𝜇M; (a, b, c 4): normal liver
HS 2𝜇M; (a5): normal liver HS 3 𝜇M; (a6): peritumoral HS 1𝜇M; (a, b, c 7): peritumoral HS 2𝜇M; (a8): hepatocellular carcinoma HS 1 𝜇M;
(a, b, c 9): hepatocellular carcinoma HS 2𝜇M.
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Figure 5: Effect of heparin treatment on topoisomerase I plasmid
relaxation activity of HepG2 and Hep3B cells (representative image
of three independent experiments). Cells were plated to 6 well plates
at 2.5 × 105 cells/plate and grown for 24 h in the presence of 5%
fetal calf serum. Subsequently, the serum was replaced with bovine
serum albumin (BSA), and the cells were exposed to 100 𝜇g/mL
heparin for 24 h (lanes 4 and 7) and 48 h (lanes 5 and 8). Cell nuclear
extracts were used for topo I relaxation activity measurements as
described. Heparin exposure for 48 hours resulted in total loss of
enzyme activity of Hep3B cells (lane 5). Heparin did not affect the
activity of HepG2 cells (lanes 4 and 5). Lane 1: DNA size standard,
1 kiloBase (kB) ladder; lane 2: plasmid control without protein (S:
superhelix, R: relaxed); lanes 3 and 6: plasmid relaxation in untreated
cells.
on topoisomerase I. Certainly, heparin and liver HS, but
not liver cancer HS, bound and inhibited topoisomerase
I plasmid relaxation in vitro [21, 44]. Our present work
also demonstrates that heparin and HS hinder the in vitro
plasmid cleavage effect of TpT. This effect was much more
obvious when cell nuclear extracts were obtained from liver
tumor specimens with low or moderate topoisomerase I
activity. This in vitro phenomenon seemed to be important
from two points of view. First, heparin or HS could protect
normal surrounding tissues with low topoisomerase I activity
from the cytotoxic action of TpT. Second, however, the
1 2 3 4 5
Figure 6: Competition of heparin and DNA for topoisomerase
I (representative image of three independent experiments). Effect
of heparin on the DNA gel retardation produced by 10U purified
topoisomerase I protein. DNA fragment of 516 base pair size
with 8 potential topo I-binding sequences was end-labeled with
digoxigenin-UTP. Thirty-five ng DNA was incubated with 10U
topoisomerase I alone or in the presence of 10 and 100 ng heparin.
Samples were run or 1% agarose, blotted to nylon membrane, and
developed with antidigoxigenin alkaline phosphatase. 1: control
DNA, without protein; 2 and 3: DNA with topoisomerase I; 4 and 5:
DNA and topoisomerase I, with 10 and 100 ng heparin, respectively.
same mechanism could rescue tumors with low or modest
topoisomerase I activity from TpT.
The HepG2 cell line with high and the Hep3B cell line
with moderate enzymatic activity served as a model to test
this hypothesis. In support of the results obtained in a
cell-free system, heparin exposure abolished the moderate
topoisomerase I activity of the Hep3B cell line, while HepG2
cells retained their enzymatic activities. As the efficacy of
TpT depends on the actual activity of topoisomerase I, it was
reasonable to expect that, if administered together, heparin
will interfere with the action of the drug. Certainly, using the
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Hep3B cell line with low topoisomerase I activity, the growth
inhibitory effect of TpT decreased in the presence of heparin,
while only a modest, transient heparin protection has been
achieved on the HepG2 cell line. However, the mechanism of
action was still a question.
Heparin alone did not affect the cell cycle. More likely, its
protective effects against TpT action were related to its topo
I binding capacity. In an assay mixture containing heparin,
recombinant topo I and labeled DNA heparin appeared
to compete with DNA for the binding of topo I. Thus,
in the presence of heparin or HS a lower proportion of
topoisomerase I could be bound covalently to DNA by TpT,
thus preventing DNA fragmentation. The binding capacity
and the amount of heparin or heparan sulfate can determine
the proportion of topoisomerase I that will not interact with
DNA. The decrease in dead cell fraction after a combined
TpT-heparin treatment provided further support to this
hypothesis.
Our results are in a good agreement with those clinical
observations that aimed to treat liver tumors with TpT.
Similarly to the HepG2 cell line, hepatoblastomas respond
well for TpT treatment [45, 46], whereas the drug efficacy on
liver cancers is modest at best [47]. In the general practice
TpT is administered without knowing the topoisomerase I
activity status of the tumors. Even though additional studies
are warranted on the subject, our current results suggest
that for maximum efficacy treatment regimens should avoid
concomitant application of heparin and a topoisomerase
inhibitor. Having said this, as HS of the tumor itself appears
to be ineffective to inhibit topoisomerase I activity, it does
not reduce the efficacy of TpT, at least not in the case of liver
carcinomas.
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